Japan's attempts to import swine flu vaccine may be too late

Aug 23, 2009 The Yomiuri Shimbun

The Japanese government might not be able to import vaccine to combat the new type of influenza -- the H1N1 virus, or swine flu -- before autumn, when an epidemic of the disease is feared will intensify, as experts want pre-import confirmation that the vaccine is safe for Japanese patients, sources familiar with the matter said.

According to the sources, the three Western pharmaceutical companies that manufacture the vaccine have submitted terms of contract, among which the government is asked to exempt them from liability in case the vaccine causes side effects. Additionally, the firms indicated they would prioritize shipments to other countries unless the contract is signed by the end of this month.

The companies likely offered such tough terms because of expectations of a new-flu vaccine shortage around October or November, when the Northern Hemisphere enters its winter flu season.

Last month, Health, Labor and Welfare Minister Yoichi Masuzoe said the nation would need vaccine for 53 million people. The health ministry was negotiating with the foreign pharmaceutical firms to import 15 million to 20 million doses to cover an expected shortage that domestic makers cannot cover.

The ministry intends to accept the contract terms so it can import the vaccine as soon as possible, the sources said. Therefore, it asked a government advisory panel to examine the advisability of importing the vaccine, which has undergone only overseas safety verification procedures, by applying the Pharmaceutical Affairs Law's "special approval" provision to this case, according to the sources.

However, many experts on the advisory panel opposed such a move, with one reportedly saying such approval cannot guarantee the safety of the vaccine because overseas vaccine-injection methods might be different from those of domestically produced vaccine, and foreign-made might contain immunopotentiating agents (that upon injection enhance ).
___

(c) 2009, The Yomiuri Shimbun
Visit the Daily Yomiuri Online at www.yomiuri.co.jp/index-e.htm/
Distributed by McClatchy-Tribune Information Services.

Explore further: Booming mobile health app market needs more FDA oversight for consumer safety, confidence

add to favorites email to friend print save as pdf

Related Stories

Japan to start developing swine flu vaccine

May 04, 2009

The Japanese Health, Labor and Welfare Ministry announced Saturday the start of vaccine development against swine flu, following the arrival of a sample of the new type of flu strain at the National Institute of Infectious ...

Bird flu vaccine declared safe by testers

Aug 28, 2006

Chinese researchers said Monday that the first round of clinical tests of a bird flu vaccine for humans have found the treatment to be safe and effective.

WHO: Swine flu vaccine on track

Aug 06, 2009

(AP) -- Swine flu vaccine manufacturers are on track to start delivering the first batches of it in September, the World Health Organization said Thursday.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

User comments : 0